Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Significance of CYP19 Genetic Polymorphism on Musculoskeletal Symptom & Complication of Aromatase Inhibitor(AI)

NCT00973505 is registered in ClinicalTrials.gov with Korea University Anam Hospital as lead sponsor.

NCT NCT00973505
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00973505 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Significance of CYP19 Genetic Polymorphism on Musculoskeletal Symptom & Complication of Aromatase Inhibitor(AI)
Lead sponsor
Korea University Anam Hospital
Phase
Observational
Overall status
Unknown status
Start date
March 31, 2009
Completion date
September 30, 2010
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

arthralgia, arthritis, breast neoplasms, genetic polymorphism